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Phenotypic Characterization of Nevus and Tumor
Patterns in MITF E318K Mutation Carrier Melanoma
Patients
Richard A. Sturm1, Carly Fox2, Phil McClenahan3, Kasturee Jagirdar1, Maider Ibarrola-Villava1,4,
Parastoo Banan3,5, Nicola C. Abbott3,5, Gloria Ribas4, Brian Gabrielli2, David L. Duffy6 and
H. Peter Soyer3,5
A germline polymorphism of the microphthalmia transcription factor (MITF) gene encoding a SUMOylation-
deficient E318K-mutated protein has recently been described as a medium-penetrance melanoma gene. In a
clinical assessment of nevi from 301 volunteers taken from Queensland, we identified six individuals as MITF
E318K mutation carriers. The phenotype for 5 of these individuals showed a commonality of fair skin, body
freckling that varied over a wide range, and total nevus count between 46 and 430; in addition, all were multiple
primary melanoma patients. The predominant dermoscopic signature pattern of nevi was reticular, and the
frequency of globular nevi in carriers varied, which does not suggest that the MITF E318K mutation acts to force
the continuous growth of nevi. Excised melanocytic lesions were available for four MITF E318K carrier patients
and were compared with a matched range of wild-type (WT) melanocytic lesions. The MITF staining pattern
showed a predominant nuclear signal in all sections, with no significant difference in the nuclear/cytoplasmic
ratio between mutation-positive or -negative samples. A high incidence of amelanotic melanomas was found
within the group, with three of the five melanomas from one patient suggesting a genetic interaction between
the MITF E318K allele and an MC1R homozygous red hair color (RHC) variant genotype.
Journal of Investigative Dermatology (2014) 134, 141–149; doi:10.1038/jid.2013.272; published online 18 July 2013
INTRODUCTION
The microphthalmia transcription factor (MITF) gene plays a
crucial role in melanocyte growth, development, and pigmen-
tation (Cheli et al., 2010). In addition, it has been proposed to
act as a lineage survival oncogene because of gene ampli-
fication in metastatic melanoma (Garraway et al., 2005).
Several different somatic mutations have been found in MITF
in melanoma tumor samples (Cronin et al., 2009), and one
recurrent germline mutation MITF E318K that predisposes to
melanoma and renal cell carcinoma has recently been
described in independent French and Australian studies
(Bertolotto et al., 2011; Yokoyama et al., 2011). This variant
allele encodes a protein that biochemically impairs MITF
SUMOylation at position 316K and is genetically associated
with increased nevus number, non-blue eye color, over a
fivefold increased risk for melanoma, and higher incidence of
multiple primary melanomas. The MITF E318K mutation has
also been studied in a group of Italian melanoma patients
(Ghiorzo et al., 2013) in whom a higher risk for melanoma
and the development of multiple primary melanomas were
again reported; notably, in this group a predisposition to
pancreatic cancer was also found. On examination of the
subtypes of melanoma in these cases, a high prevalence of
nodular melanoma was described (Ghiorzo et al., 2013),
and it has been suggested that the mutated MITF E318K
protein may direct an altered transcription program in
melanocytic cells (Bertolotto et al., 2011; Yokoyama et al.,
2011) and manifest in characteristic histopathological or
immunohistochemical (IHC) (Bertolotto et al., 2011) con-
sequences for melanomas in carrier individuals.
We have initiated a study of nevi in volunteers from the
southeast Queensland area (Douglas et al., 2011; McClenahan
et al., 2012) to determine the pigmentation phenotype, the
nevus phenotype, and the dermoscopic nevus subtypes to
combine this data set with genotypic comparisons of these
individuals. In doing so, six individuals, all of whom were
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multiple primary melanoma patients, were identified as MITF
E318K carriers. We have used this sample set to examine
whether there is any commonality in the pigmentation or nevus
phenotype, including number, distribution, color, and size of
nevi, as well as in the dermoscopic or IHC staining pattern of
nevi and melanoma samples, that may distinguish these patients
from the normal population and from other melanoma patients.
RESULTS
Identification and phenotypic characteristics of MITF mutation
carrier melanoma patients compared with noncarrier melanoma
patients
We clinically assessed 288 of the 301 subjects in our study for
a range of pigmentation characteristics and nevus phenotypes.
This group consisted of 168 individuals with a personal history
of melanoma, 31 with a first-degree relative with melanoma,
95 without such a history, and 7 unable to be classified.
Several of the melanoma patient volunteers were not able to
fully participate in the physical assessment protocol, and some
of the controls who provided saliva samples were omitted;
however, all participants were genotyped for a number of
pigmentation and nevogenic genes (Duffy et al., 2010b). This
included the rs149617956*G/A MITF E318K polymorphism
(Bertolotto et al., 2011; Yokoyama et al., 2011), with six
individuals found to be heterozygous carriers of this allele in a
cohort of five males and one female (Table 1). Each of these
six individuals were screened and found to be without
mutation at the CDKN2A locus. Two red-haired individuals,
149DC and 176SP, were melanocortin-1 receptor (MC1R) R/R
homozygotes, as expected (Beaumont et al., 2011). There was
only one IRF4 (IFN regulatory factor 4) rs12203592*C/T
carrier identified as 130MV who was a heterozygote; this
single-nucleotide polymorphism has previously been
associated with lower nevus counts in adults in the
homozygous T/T state (Duffy et al., 2010a). Five of these six
patients were phenotyped following the protocol described by
Douglas et al. (2011).
All these five individuals were fair skinned, and their body
freckling scores varied over a wide range, being highest in
patient 149DC who was red haired and an MC1R R/R
homozygote carrier, an association that we have previously
reported (Duffy et al., 2004). This patient also recorded the
lowest number (46) of total nevi above 2 mm over the whole
body in the group, with all others having much higher scores
and reaching a maximum of 430 in 130MV (Table 1). Notably,
all MITF E318K patients had suffered from multiple primary
melanomas, ranging from 2 to 5 (Table 1), compared with a
recurrence rate of 39.7% seen for the MITF WT melanoma
patients (P¼ 0.003); this figure is in line with that reported
for other melanoma cohorts, ranging between 22 and 40%
(Baxter et al., 2008; Salama et al., 2013). None of the control
or unknown subjects were found to be carrying the MITF
E318K polymorphism, with an allele frequency of 0.015 in our
199 individuals at high risk for melanoma.
Nevus and melanoma patterns of MITF mutation carrier patients
The total body nevus counts of these patients were followed
up by recording nevus distribution, size, profile, color, and
dermoscopic overall morphology of nevi above 5 mm all over
the body, and included those 42 mm on the back (Table 2).
Although an increase in the mean of total nevi was apparent
when comparing the MITF E318K carriers with the MITF wild-
type (WT) melanoma patients, this became highly significant
(P¼0.008) when nevi 45 mm were considered with counts of
84.2 (95% confidence interval (CI) 24.5–143.9) and 32.6 (95%
CI 26.7–38.4) for the two groups, respectively (Table 2). The
major contribution to the difference in nevi 45þ2 mm on the
back were greater reticular nevus counts of 55.4 (95% CI 33.9–
76.8) and 20.3 (95% CI 16.2–24.4; P¼0.004), respectively.
The predominant dermoscopic signature pattern of MITF E318K
patients was reticular (130MV, 149DC, 155IN), and then
nonspecific (158RP, 176SP). The site of melanoma, its type,
and its depth ascertained from pathology reports indicated that
the major site of occurrence in these patients was on the back
(P¼0.006), followed by the leg, arm, and abdomen, possibly
indicating a propensity for UVR-exposed sites. Of the total
number of 18 melanomas excised from this cohort, 8 were
melanoma in situ, including one lentigo maligna, with the
remaining 10 ranging in depth from 0.15 to 2.9 mm, with one
outlier at 9 mm. The 20% incidence of melanoma arising from
preexisting nevi in the MITF E318K carriers (Table 2) is similar
to that reported in studies of other multiple melanoma patients
(Murali et al., 2012). Further, there were four amelanotic
melanomas identified (Table 1), three of them in 149DC, with
body photographs and representative nevi of this patient shown
in Figure 1, and one in 130MV (other patients are shown in
Supplementary Figure S1 online). The incidence of amelanotic
melanoma of 30.7% in MITF E318K carrier patients is much
greater than the generally reported frequency of 2–8% (Jaimes
et al., 2012; McClain et al., 2012).
IHC analysis of nevi and melanoma tumors excised from MITF
mutation carriers
Excised melanocytic lesions and accompanying pathology
analyses were available for four MITF E318K mutation carrier
patients (130MV, 149DC, 176SP, and M004RR), and could
be compared with a matched range of MITF WT melanocytic
lesion samples. Any melanocytic lesion from the genotyped
patients was considered for histopathological examination and
IHC analysis, provided there was sufficient tissue to permit
sectioning and IHC staining. The sample set of 39 lesions
consisted of 19 from mutation carriers and 20 from WT
patients (Table 3). Comparisons were made between benign
and dysplastic nevi, as well as between four melanomas from
mutation carriers (149DC and M004RR) and two from an
MITF WT patient (17DC) who had also suffered from multiple
primary melanomas. The staining patterns for MITF protein
(Granter et al., 2002) in representative melanoma sections are
shown in Figure 2, and a comparison is made between
melanoma in situ (Figure 2a) and invasive melanoma
(Figure 2b) for MITF E318K tumors with in situ melanoma
(Figure 2c) for an MITF WT sample. An intense MITF nuclear
staining pattern is apparent in all sections, with no significant
difference seen in the degree of nuclear/cytoplasmic ratio
between mutation-positive or -negative samples, consistent
with transfection studies of other SUMOylation-deficient
RA Sturm et al.
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mutations of the MITF protein (Murakami and Arnheiter,
2005), nor between stages. However, nests were seen to
express the highest density of immunoreactivity, and MITF
E318K tumors had fewer samples with cytoplasmic staining
(only 3 of 19). This similarity of staining patterns between
mutant and WT melanocytic lesions was also seen using two
MITF target proteins, apurinic/apyrimidinic endonuclease 1
(APE1) (Liu et al., 2009) and cyclin-dependent kinase 2
(CDK2; Table 3) (Du et al., 2004). Further, there was no
difference in the average proliferation index as measured by
Ki67 staining of comparative sections; however, the invasive
melanomas (as shown in Figure 2b) demonstrated the greatest
level of reactivity (10%).
DISCUSSION
There are now a multitude of genetic loci that are known to
influence melanoma risk (Law et al., 2012), but it is imperative
to understand those that influence the number and behavior
of nevi as these confer the greatest individual risk of
melanomagenesis. In this study the germline missense
substitution MITF E318K, known as a medium-penetrance
melanoma gene, was found only in our melanoma patient
cohort of 168 individuals, excluding other at-risk individuals,
giving an allele frequency of 0.018. This is in line with other
reports of this mutant allele in melanoma cases—0.017 in
Australian/UK (Yokoyama et al., 2011), 0.014 in French
(Bertolotto et al., 2011), and 0.009 in Italian samples
(Ghiorzo et al., 2013). Also consistent is the fact that each
of the six patients whom we have characterized as carriers of
the MITF E318K polymorphism had suffered from multiple
primary melanomas and, apart from 149DC, relatively high
nevus counts (Yokoyama et al., 2011). There was a high
incidence of melanoma in situ and only one thick melanoma
of 9 mm, a finding that does not support the suggestion that the
Figure 1. Total body and dermoscopic images from patient 149DC. The photograph of the back of patient 149DC is shown together with nine dermoscopic
images chosen as representative of the nevi in this patient who has a reticular signature pattern. A total of 34 nevi45 mm in diameter on all body sites and 42 mm
in diameter on the back were identified on this patient. Excluding small nevi on the back results in 28 nevi 45 mm on the whole body. Of the 15 nevi on the back
(median size 5.1 mm), 6 are 42 mm buto5 mm in diameter and 9 are 45 mm in diameter. Of these, 12 are reticular and 3 homogenous/unspecific. In addition,
2 are pink in color, 11 are light brown, and 2 are mid-brown. On other body sites, 1 nevus was identified on the head/neck, 4 on the abdomen/chest, 4 on the
upper limbs, and 10 on the lower limbs. Nevus color was either pink or light brown for all of them.
Table 3. IHC staining patterns of nevi and melanomas excised from MITF E318K allele1 carriers and MITF WT2
patients
Intensity3,4 Nuclear Cytoplasmic
E318K WT P-value5 E318K WT P-value5 E318K WT P-value5
MITF 2.26 (0.55) 2.3 (0.66) 0.42 19/19 20/20 1 3/19 9/20 0.08
APE1 2.42 (0.9) 2.65 (0.67) 0.30 19/19 20/20 1 12/19 16/20 0.30
CDK2 2.11 (0.88) 2.4 (0.75) 0.46 14/19 12/20 0.5 17/19 20/20 0.23
Ki674 2.21 2.3 0.46
Abbreviations: APE1 apurinic/apyrimidinic endonuclease 1; CDK2, cyclin-dependent kinase 2; IHC, immunohistochemistry; MITF, microphthalmia
transcription factor; WT, wild type.
1Sample set included 4 benign nevi, 11 dysplastic nevi, 2 melanomas in situ, and 2 primary melanomas.
2Sample set included 3 benign nevi, 15 dysplastic nevi, 1 melanoma in situ, and 1 primary melanoma.
3Intensity was scored on a three-point scale (1–3) per slide and represented as the mean (±SD) of these values.
4As an average of the percentage of tumor cells stained within the lesions, range was 1–10%, with none expressing 0%.
5Fisher’s exact test.
6Mann–Whitney test.
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MITF E318K mutation is associated with the development of a
nodular subtype of melanoma (Ghiorzo et al., 2013); rather, it
is more in agreement with there being no association with
Breslow thickness as reported in the Australian/UK study
(Yokoyama et al., 2011). It is possible that greater
surveillance of those at high risk for melanoma in Australia
could explain these differences as these cases of melanoma
are more likely to be picked up early before progression to a
nodular stage (Murali et al., 2012).
Whole-body clinical examination of melanocytic nevi
found on five MITF E318K patients did not distinguish any
commonality of pigmentation phenotype, apart from fair skin.
Dermoscopic analysis revealed that the predominant nevus
signature pattern in nevi 45þ2 mm on the back was of a
reticular type in both MITF E318K and WT patients, which
was also the subtype with the greatest increase in number
when the two groups were compared (Table 2). There was a
high incidence of amelanotic melanomas found within the
group, with 4 of 13 excised lesions presenting as nonpigmen-
ted melanoma; as 3 of the 5 melanomas from patient 149DC
were amelanotic, it is possible that a genetic interaction
between the MITF E318K allele and his MC1R red hair color
(RHC) homozygous R/R genotype is the basis of this pheno-
type. Unfortunately, the pathology reports detailing the pig-
mentation status of the five melanoma lesions for patient
176SP, who was also of this MC1R genotype, were not
available to confirm this observation. Previous association of
the MC1R RHC alleles with amelanotic melanoma and
depigmented nevi lends support to this interaction (Zalaudek
et al., 2009; Curchin et al., 2012), and possibly for the high
number of multiple primaries. Moreover, a genetic interaction
has earlier been described for the high-penetrance familial
melanoma gene CDKN2A and co-carriers of homozygous
MC1R RHC alleles for the increasing incidence of multiple
primary melanomas (Peris et al., 2004; Goldstein et al., 2005;
Eliason et al., 2007; Pastorino et al., 2008). A higher frequency
of MC1R RHC alleles has also been reported in CDK4 gene
mutation melanoma–prone family members with multiple
primary melanomas (Puntervoll et al., 2013).
A report on the dermoscopic features of primary melanomas
in nine high-risk CDKN2A mutation carrier patients from the
Spanish population found that the mean ABCD total dermo-
scopy score was significantly higher in those with MC1R
non-RHC genotype (Cuellar et al., 2009) compared with those
who carried two MC1R RHC variant alleles. Although the
melanomas in CDKN2A patients homozygous for MC1R RHC
alleles were more difficult to diagnose, with less color and
fewer structures, atypical vessels were observed. The total
dermoscopy score has been further examined in a larger group
of 876 dysplastic nevi and 21 melanomas taken from high-risk
CDKN2A European melanoma patients (Quint et al., 2012).
Here it was reported that a pigment network, dark brown
color, and streaks were more common in those without an
MC1R RHC allele, although in contrast to the earlier report
there was no difference in the total dermoscopy score of those
who carried two MC1R RHC alleles. The dermoscopic and
histopathological patterns of nevi associated with BRAF
mutations have been recently reported (Zalaudek et al.,
2011). Although the sensitivity of detection of BRAF changes
among nevi was highly dependent on the detection method
used, possibly because of clonal heterogeneity within the cells
a
b
c
MITF E318K
MITF E318K
MITF WT
Figure 2. Microphthalmia transcription factor (MITF)-staining patterns of
melanomas from E318K mutation and wild-type (WT) carriers. The panels are
representative staining patterns of melanomas obtained from (a, b) MITF E318K
mutant and (c) WT patients. (a) An amelanotic melanoma in situ taken from the
upper back of patient 149DC. (b) An invasive melanoma (Breslow thickness
1.1 mm) from the shoulder of M004RR. (c) A melanoma in situ respective to an
invasive melanoma (Breslow thickness 0.42 mm) from the left upper back of
a 43-year-old male MITF WT patient, 17DC. There is intense staining of
melanocytic nuclei in each of the sections with no variation in the level of
staining or pattern dependent upon MITF mutation status; however, there is an
increased signal apparent when the cells form nests. Scale bars¼ 100 (a), 200
(b), and 300mm (c).
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of the nevus, BRAF mutations were more frequent in globular
nevi, and in mixed reticular/homogeneous nevi with
peripheral globules possibly representing growing nevi. The
frequency of globular nevi in the five MITF E318K carriers
in this report varied between patients; although the mean
frequency was greater than MITF WT patients, this increase
was not statistically significant (Table 2), and does not suggest
that this mutation will be acting to force the continuous
growth of nevi; more likely, the somatic mutations in BRAF
within the nevi must occur to drive growth.
It is clear from genetic and biochemical studies that the
MITF protein acts as a transcription factor that regulates a suite
of genes involved in pigment synthesis and cell cycle control
(Cheli et al., 2010). As this is partly achieved through the MITF
target gene APEX1 encoding APE1 and CDK2, we chose to
perform IHC with antibodies to these proteins. Our finding
of no statistical difference in staining patterns between
MITF mutation-positive and -negative sections supports the
conclusion that protein stability and nucleocytoplasmic
partitioning are not affected by the E318K-induced
SUMOylation deficiency of the MITF protein (Bertolotto
et al., 2011; Yokoyama et al., 2011); rather, some differential
regulation of gene expression will explain the increased risk for
melanomagenesis caused by this mutation. It is clear that this
may be a subset of MITF targets, but as the APE1 and CDK2
proteins did not differ in staining characteristics between
mutation-positive and -negative sections the pathways
concerned will have to be further characterized. MITF-
directed gene regulation in melanocytic cell responses to
reactive oxygen species stress (Liu et al., 2009), DNA
damage (Beuret et al., 2011; Strub et al., 2011), the hypoxic
response (Feige et al., 2011; Cheli et al., 2012), and melanoma
initiator cell behavior and phenotype switching (Cheli et al.,
2011; Thurber et al., 2011) are obvious candidates that must
now be characterized in MITF E318K carrier patients.
MATERIALS AND METHODS
Study samples and DNA extraction
Consecutive high-risk melanoma patients seen between October
2009 and October 2012, defined as those with a personal or a first-
degree family member with a history of melanoma, were recruited
from the Melanoma Unit and Dermatology Department of the
Princess Alexandra Hospital (PAH) or from Private Practice (HPS),
which treats clients from the Southeast Queensland region. Moderate-
and low-risk melanoma volunteers were recruited through advertise-
ment of our study throughout the PAH during 2010 and by direct
contact through letters to participants in the Brisbane Twin Nevus
Study (BTNS) requesting they volunteer (Duffy et al., 2010a). There
were 301 individuals who provided saliva samples using an Oragene-
DNA self-collection kit (DNA Genotec, Ottawa, ON, Canada) for
genomic DNA processing. Every individual gave written informed
consent; the study was conducted according to the Declaration of
Helsinki Principles, and the University of Queensland HREC and
QIMR HREC approved the ascertainment of samples.
Measures and dermoscopy
Of the 301 participants, 288 were able to undergo a detailed whole-
body examination including digital recording of images from 16 body
sites and individual dermoscopic images of all significant nevi
recorded using a system for sequential total-body photography and
dermoscopy (FotoFinder Systems GmbH, Bad Birnbach, Germany).
Significant nevi were classified as those 42 mm on the back of both
male and female participants and on the lower limbs of female
participants, and those 45 mm at all other body sites (excluding
scalp, buttocks, mucosal surfaces, and genitalia of both sexes). All
significant nevi were classified in terms of their predominant dermo-
scopic pattern contributing to at least one-third of the lesions’ surface
area (globular; reticular; globular/structureless with reticular rim;
reticular/structureless with globular rim; and nonspecific, which
includes homogenous nevi). Dermoscopically classified nevi were
then grouped by age bracket (10–39 years and 40þ years) and body
site (head/neck, abdomen/chest, back, upper limbs, and lower limbs)
for high- and moderate/low-risk melanoma groups. The signature
nevus pattern (defined as the pattern seen in 440% nevi) (Scope
et al., 2006) was calculated for each individual.
A clinical assessment using standardized pigmentation character-
istics was performed: hair color rated on a 5-category scale (1, fair/
blonde; 2, light brown; 3, red/auburn; 4, dark brown; and 5, black);
eye color (1, blue/gray; 2, green/hazel; and 3, brown, which
included standardized close-up digital imaging of the eyes to assess
pigmentation pattern); skin color (inner upper left arm, innate/
facultative skin color (visually rated as 1, fair/pale; 2, medium; and
3, olive/dark, and also analyzed by spectrophotometry of the volar
and dorsal skin of the arm) (CIE (L*, a*, b*) color space). Freckling
density was recorded on a four-point scale (0, none; 1, mild/
infrequent/sparse; 2, moderate/evenly distributed; and 3, severe) at
three body sites (face, dorsum of the right hand, and shoulders), with
a composite freckling score constructed by summing the scores for
these three sites (Duffy et al., 2004).
DNA sequencing and genotyping
Genomic DNA was subjected to automated DNA sequence analysis
of PCR-amplified fragments covering the MC1R coding region (Box
et al., 2001), CDKN2A exon 1a and exon 2 (Harland et al., 2008)
using ABI PRISM Big Dye Terminator Sequencing (Applied Biosystems,
Foster City, CA), with reactions processed by the Australian Equine
Genetics Research Centre (AEGRC, Brisbane, Australia). Single-
nucleotide polymorphism genotyping was performed using iPLEX
Gold chemistry on a MALDI-TOF Mass Spectrometer (Sequenom, San
Diego, CA) (Duffy et al., 2010b). TaqMan single-nucleotide polymor-
phism genotyping assays (Cook et al., 2009) were performed in a 96-
or 384-well-plate format using a 7500 real-time PCR system and
analyzed using 7500 Software (Applied Biosystems). Genotyping of
rs149617956 MITF-E318K was carried out with Custom-designed
Taqman assay AHWR8XV (Applied Biosystems).
IHC of nevi and melanoma tumor samples
A series of 32 lesions and pathology reports were obtained from the
PA Hospital pathology archives and a further 7 lesions were collected
from Sullivan and Nicolaides Pathology in Brisbane, Australia. Slides
were deparaffinized and rehydrated through xylene to water. Antigen
retrieval was performed with a 5-min boiling cycle in 0.01 M citrate
buffer in a commercial decloaker. Peroxidase block was performed
with 3% hydrogen peroxide for 15 minutes. Nonspecific binding was
blocked with donkey serum/BSA in Tris-buffered saline for 30 minutes
before overnight incubation with the primary antibody. The primary
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antibodies used were monoclonal mouse anti-human APE1 (ab194,
1:10,000; AbCam, Cambridge, MA), monoclonal mouse anti-human
Ki67 (M7240, 1:100; Dako, Campbellfield, VIC, Australia), mono-
clonal mouse anti-human MITF (M3621, 1:30; Dako), and polyclonal
rabbit anti-human CDK2 (sc163 M2, 1:200; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA). Secondary antibody was Vector IMMPRESS
(Burlingame, CA) anti-mouse or anti-rabbit. Vector ImmPACT NovaRED
peroxidase substrate was applied as a chromogen for visualization of
the immunoreaction. Hematoxylin was used for counterstaining.
Negative controls were obtained by omitting the primary antibody.
Slides were mounted using ClearMount mounting solution (Invitro-
gen, Mulgrave, VIC, Australia) and coverslipped with Xylene and
Entellan (Merck Millipore, Kilsyth, VIC, Australia) mounting media.
They were then scanned using an Aperio (Vista, CA) slide scanner
at  20 magnification.
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